



ALMA MATER STUDIORUM
UNIVERSITÀ DI BOLOGNA
DIPARTIMENTO DI MEDICINA SPECIALISTICA
DIAGNOSTICA E SPERIMENTALE

POLICLINICO DI
SANT'ORSOLA

SERVIZIO SANITARIO REGIONALE
EMILIA-ROMAGNA
Azienda Ospedaliero - Universitaria di Bologna

New Drugs in Hematology

President: Pier Luigi Zinzani

Co-President: Michele Cavo

**Bologna,
Royal Hotel Carlton**

May 18-20, 2022

PROGRAM

BOLOGNA BOLOGNA, ROYAL HOTEL CARLTON

Auspices

**ALMA MATER STUDIORUM
UNIVERSITÀ DEGLI STUDI DI BOLOGNA**


REGIONE EMILIA-ROMAGNA

**AZIENDA OSPEDALIERO-UNIVERSITARIA
DI BOLOGNA**

**AIL ASSOCIAZIONE ITALIANA CONTRO
LE LEUCEMIE - LINFOMI E MIELOMA**
SEZIONE DI BOLOGNA

SIE - SOCIETÀ ITALIANA DI EMATOLOGIA

**SIES - SOCIETÀ ITALIANA DI EMATOLOGIA
SPERIMENTALE**



Faculty

Stephen M.	Ansell	Rochester, USA	Maurizio	Martelli	Rome, Italy
Martine	Bagot	Paris, France	Matthew J.	Matasar	New York, USA
Nizar J.	Bahlis	Calgary, Canada	Anthony R.	Mato	New York, USA
Wilma	Barcellini	Milan, Italy	Craig H.	Moskowitz	Miami, USA
Massimiliano	Bonifacio	Verona, Italy	Susan M.	O' Brien	Irvine, USA
Francesca	Bonifazi	Bologna, Italy	Owen A.	O'Connor	Charlottesville, USA
Massimo	Brescia	Rome, Italy	Francesco	Passamonti	Varese, Italy
Elizabeth L.	Budde	Duarte, USA	Alexander E.	Perl	Philadelphia, USA
John C.	Byrd	Columbus, USA	Antonio	Pinto	Naples, Italy
Paolo F.	Caimi	Cleveland, USA	Carlos A.	Ramos	Houston, USA
Fausto	Castagnetti	Bologna, Italy	Vincent	Ribrag	Villejuif, France
Michele	Cavo	Bologna, Italy	Paula	Rodriguez-Otero	Pamplona, Spain
Bruce D.	Cheson	Washington, USA	Gianantonio	Rosti	Meldola - FC, Italy
Graham	Collins	Oxford, UK	Marco	Ruella	Philadelphia, USA
Paolo	Corradini	Milan, Italy	Sergio	Rutella	Nottingham, UK
Antonio	Cuneo	Ferrara, Italy	Giuseppe	Saglio	Orbassano - TO, Italy
Antonio	Curti	Bologna, Italy	Gilles	Salles	New York, USA
Naval G.	Daver	Houston, USA	David A.	Sallman	Tampa, USA
Michel	Delforge	Leuven, Belgium	Stephen J.	Schuster	Philadelphia, USA
Michael	Dickinson	Melbourne, Australia	Laurie	Sehn	Vancouver, Canada
Catherine S.M.	Diefenbach	New York, USA	John	Seymour	Melbourne, Australia
Hermann	Einsele	Würzburg, Germany	Tanya	Siddiqi	Duarte, USA
Andrés J.M.	Ferreri	Milan, Italy	Michele	Spina	Aviano - PN, Italy
Francine	Foss	New Haven, USA	Eytan M.	Stein	New York, USA
Valentin	Garcia-Gutierrez	Madrid, Spain	Paolo	Strati	Houston, USA
Heinz	Gisslinger	Wien, Austria	Marion	Subklewe	Munich, Germany
Florian H.	Heidel	Greifswald, Germany	Max S.	Topp	Würzburg, Germany
Alex F.	Herrera	Duarte, USA	Frits	van Rhee	Little Rock, USA
Peter	Hillmen	Leeds, UK	Alessandro M.	Vannucchi	Florence, Italy
Martin	Hutchings	Copenhagen, Denmark	Adriano	Venditti	Rome, Italy
Wojciech	Jurczak	Kraków, Poland	Srdan	Verstovsek	Houston, USA
Robert J.	Kreitman	Bethesda, USA	Michael	Wang	Houston, USA
Nicolaus M.	Kroeger	Hamburg, Germany	Andrew H.	Wei	Melbourne, Australia
John	Kuruvilla	Toronto, Canada	Andrew D.	Zelenetz	New York, USA
Frederick	Locke	Tampa, USA	Pier Luigi	Zinzani	Bologna, Italy
Enrica	Marchi	Charlottesville, USA			

Wednesday, May 18, 2022

9.00 a.m. *Welcome and introduction*

Three recent “impressive” stories

Chairman: P. Corradini

9.15 a.m. *Ibrutinib - J.C. Byrd*

9.40 a.m. *Venetoclax - J. Seymour*

10.05 a.m. *CAR-T - S.J. Schuster*

SESSION I: Acute leukemia

Chairmen: A. Curti, A. Venditti

10.45 a.m. *Immunolandscapes in AML:
chemoresistance and response to immunotherapy - S. Rutella*

11.05 a.m. *Checkpoint inhibitors - N.G. Daver*

11.20 a.m. *BiTes in AML - M. Subklewe*

11.35 a.m. *IDH inhibitors - E.M. Stein*

11.50 a.m. *CAR-T cells for adult ALL - M. Ruella*

12.05 p.m. *New treatment approaches in TP53 mutated AML:
APR-246 - D.A. Sallman*

12.20 p.m. *Targeting CD47 by monoclonal antibody - D.A. Sallman*

12.35 p.m. *HDM2 inhibitor - E.M. Stein*

12.50 p.m. *Inotuzumab versus Blinatumomab in ALL - M.S. Topp*

1.05 p.m. *CC486 - A.H. Wei*

1.20 p.m. *FLT3 inhibitors - A.E. Perl*

1.35 p.m. **Lunch**

SESSION II: Hodgkin's lymphoma


Chairman: P.L. Zinzani

- 2.45 p.m.** Status of the art of treatment - *C.H. Moskowitz*
- 3.05 p.m.** Anti-PD1: Nivolumab and Pembrolizumab - *S.M. Ansell*
- 3.20 p.m.** Brentuximab vedotin - *A.F. Herrera*
- 3.35 p.m.** New combo-steps - *C.S.M. Diefenbach*
- 3.50 p.m.** Camidanlumab tesirine - *G. Collins*
- 4.05 p.m.** AFM13 - *S.M. Ansell*
- 4.20 p.m.** CAR-T - *C.A. Ramos*

Lectures

Chairman: M. Spina

- 4.45 p.m.** Siltuximab - *F. van Rhee*
- 5.05 p.m.** Rituximab biosimilars - *W. Jurczak*
- 5.25 p.m.** Ravulizumab: the new frontier in PNH therapy - *W. Barcellini*
- 5.45 p.m.** Moxetumomab pasudotox - *R.J. Kreitman*



Lecture

Chairman: A.J.M. Ferreri

8.00 a.m. Lenalidomide: one drug for each season - *B.D. Cheson*

SESSION III: Chronic myeloid leukemia

Chairman: G. Saglio

8.30 a.m. Asciminib alone - *M. Breccia*

8.45 a.m. Asciminib in combination - *F. Castagnetti*

9.00 a.m. Ponatinib - *G. Rosti*

9.15 a.m. Bosutinib - *V. Garcia-Gutierrez*

9.30 a.m. Nilotinib, the correct dose - *M. Bonifacio*

9.45 a.m. Treatment free remission - *G. Saglio*

SESSION IV: Classical Ph1-neg myeloproliferative neoplasms

Chairmen: F. Passamonti, A.M. Vannucchi

10.10 a.m. Status of the art of treatment - *S. Verstovsek*

10.30 a.m. Ruxolitinib in polycitemia - *A.M. Vannucchi*

10.45 a.m. Interferons in polycitemia vera - *H. Gisslinger*

11.00 a.m. Ruxolitinib in myelofibrosis - *F.H. Heidel*

11.15 a.m. New drugs in myelofibrosis - *F. Passamonti*


11.30 a.m. Transplant in myelofibrosis: when and how - *N.M. Kroeger*

SESSION V: Non-Hodgkin's lymphoma (I)

Chairman: A. Pinto

- 12.00 p.m. Tafasitamab - G. Salles
- 12.15 p.m. Epcoritamab - M. Hutchings
- 12.30 p.m. Glofitamab - M. Dickinson
- 12.45 p.m. Mosunetuzumab - E.L. Budde
- 1.00 p.m. Odronextamab - M.S. Topp
- 1.15 p.m. Polatuzumab vedotin - L. Sehn
- 1.30 p.m. Loncastuximab tesirine - P.F. Caimi

- 1.45 p.m. **Lunch**



SESSION VI: Non-Hodgkin's lymphoma (II)

Chairmen: M. Martelli, O.A. O'Connor

- 2.50 p.m. Zilovertamab - *M. Wang*
- 3.05 p.m. Mogamulizumab - *M. Bagot*
- 3.20 p.m. Pirtobrutinib - *M. Wang*
- 3.35 p.m. Zanubrutinib - *P.L. Zinzani*
- 3.50 p.m. Selinexor - *J. Kuruvilla*
- 4.05 p.m. Valemetostat - *F. Foss*
- 4.20 p.m. ASTX660 - *O.A. O'Connor*
- 4.35 p.m. HMPL-523 - *P. Strati*
- 4.50 p.m. PROTAC Therapies - *O.A. O'Connor*

- 5.15 p.m. **Coffee break**

SESSION VII: Non-Hodgkin's lymphoma - PI3K inhibitors (III)

Chairman: B.D. Cheson

- 5.30 p.m. Umbralisib - *E. Marchi*
- 5.45 p.m. Copanlisib - *M.J. Matasar*
- 6.00 p.m. Duvelisib - *P.L. Zinzani*
- 6.15 p.m. Parsaclisib - *V. Ribrag*
- 6.30 p.m. Zandelisib - *A.D. Zelenetz*
- 6.45 p.m. HMPL-689 - *P. Strati*

Friday, May 20, 2022

Lecture

Chairman: F. Bonifazi

9.00 a.m. Donor-derived CAR-T cells - *F. Locke*

SESSION VIII: Chronic Lymphocitic Leukemia

Chairman: A. Cuneo

9.30 a.m. Ibrutinib - *S.M. O'Brien*

9.45 a.m. Idelalisib - *A.D. Zelenetz*

10.00 a.m. Venetoclax - *J. Seymour*

10.15 a.m. Acalabrutinib - *J.C. Byrd*

10.30 a.m. Zanubrutinib - *P. Hillmen*

10.45 a.m. Pirtobrutinib - *A.R. Mato*

11.00 a.m. CAR-T - *T. Siddiqi*

11.15 a.m. Duvelisib - *A.R. Mato*

SESSION IX: Multiple myeloma

Chairmen: N.J. Bahlis, M. Cavo

11.45 a.m. Melflufen and CELMODs - *M. Delforge*

12.05 p.m. XPO1 and BCL-2 inhibitors - *N.J. Bahlis*

12.25 p.m. CAR-T cells - *P. Rodriguez-Otero*

12.45 p.m. Bi-specific and drug-coniugate
monoclonal antibodies - *H. Einsele*

1.15 p.m. **Conclusions and "Arrivederci"**



GENERAL INFORMATION

MEETING VENUE

Royal Hotel Carlton

Via Montebello, 8 - 40121 Bologna, Italy

Phone +39 051 249361 - Fax +39 051 249724

www.royalhotelcarltonbologna.com

OFFICIAL LANGUAGE

English

REGISTRATION FEE

Euro 400,00 (Italian VAT included)

The registration fee includes: conference kit, participation in the scientific sessions, certificate of attendance, coffee breaks, lunches.

BADGE

All registered participants, speakers and sponsors will be given a badge which they must be worn in order to be admitted to the scientific sessions.

CERTIFICATE OF ATTENDANCE

A certificate will be given to all participants at the end of the meeting.

ITALIAN CME CREDITS

An Italian CME application has been submitted as follows:

- Provider Studio ER Congressi SRL: ID 828-281246.
- **No. 6 CME** credits for Physicians (disciplines: Allergology and Clinical Immunology, Dermatology and Venereology, Hematology, Oncology, Pathological Anatomy, Clinical Biochemistry, Clinical Pathology), Biologists and Chemists.
- Educational objective: "linee guida-protocolli-procedure".

EUROPEAN CME CREDITS

The program of the "New Drugs in Hematology" has been reviewed and approved for CME accreditation by the European Board for Accreditation in Hematology (EBAH), an independent accreditation body endorsed by EHA. The EBAH Unit has approved this educational activity for no. 22 CME credits for Physicians, Biologists and Chemists. To request credits, please fill out the form and return it to the registration desk at the end of the meeting. We remind you that it is necessary to have an EBAH-CME account in order to claim for credits. Attendees can create an EBAH-CME account registering on the website: <http://ebah.org>.

CHANGES

Parts of the program may be changed without notice.

ACKNOWLEDGEMENTS

abbvie

Celgene | Bristol Myers Squibb™
Company

Janssen Oncology
PHARMACEUTICAL COMPANIES OF Johnson & Johnson

MSD

AstraZeneca

BeiGene



EUSA Pharma

GILEAD

Takeda

ADC
THERAPEUTICS

astex
A member of the Otsuka group

Lilly

Genmab

gsk

HUTCHMED

Incyte

Karyopharm™
Therapeutics

MEI Pharma

morphosys

SANDOZ
A Novartis
Division

TESSA
THERAPEUTICS

New Drugs in Hematology

Scientific Secretariat

Pier Luigi Zinzani

Istituto di Ematologia

“Lorenzo e Ariosto Seràgnoli”

Via Massarenti, 9 - 40138 Bologna, Italy

Organizing Secretariat

Studio E.R. Congressi

Via De' Poeti, 1/7 - 40124 Bologna, Italy

Phone +39 051 4210559 - Fax +39 051 4210174

e-mail: ercongressi@ercongressi.it

www.ercongressi.it